Amprenavir: A review of its clinical potential in patients with HIV infection

Drugs

Volumn 60, Issue 6, 2000, Pages 1383-1410

  Noble, S ^a   Goa, K L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; PLACEBO; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CROSS RESISTANCE; CYTOTOXICITY; DIGESTIVE SYSTEM FUNCTION DISORDER; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; METABOLIC DISORDER; NONHUMAN; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; RASH; REVIEW;

EID: 0034519576     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060060-00012     Document Type: Review

References (89)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. A risk-benefit assessment of HIV protease inhibitors
3. HIV-protease inhibitors
4. Antiretroviral drug guidelines for the treatment of HIV infection: Should protease inhibitors always be included in the initial regimen or not?
5. Protease inhibitors for the treatment of human immunodeficiency virus infection
6. 141W94
7. In vitro effect of alpha l-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: A comparative study with other relevant HIV protease inhibitors
8. An overview of the preclinical development of the HIV protease inhibitor VX-478 (141W94)
9. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy
10. In vitro antiviral activity of 141 W94 (VX-478) in combination with other antiretroviral agents
11. 1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors
12. Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease
13. Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease. Reply
14. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro
15. A new method for evaluation of combination chemotherapy regimens: Application to abacavir (1592U89-ABC) and amprenavir (141W94-APV)
16. Amprenavir (141W94) in combination with 1592U89 is highly synergistic in vitro
17. Adefovir (PMEA) and PMPA show synergistic or additive inhibition of HIV replication in vitro in combination with other anti-HIV agents
18. Two- and three-protease inhibitor combinations against zidovudine-sensitive and zidovudine-resistant HIV-1 isolates in vitro
19. Parallel decrease of CD38++CD8 cell and viremia in primary HIV infection (PHI) patients on quadruple HAART (ZDV/3TC/abacavir/amprenavir)
20. Intervention with quadruple HAART [Combivir (COM)/abacavir (ABC)/amprenavir (APV)] intervention during primary HIV-1 infection (PHI) is associated with rapid viraemia clearance and decrease of immune activation
21. Durable activity of Ziagen (abacavir, 1592, ABC) combined with protease inhibitors (PI) in antiretroviral therapy-naïve subjects
22. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy
23. 1 acid signaling by the HIV protease inhibitor indinavir
24. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro
25. HIV protease inhibitors stimulate hepatic triglyceride synthesis
26. Effect of HIV-protease inhibitors on in vitro adipogenesis and in vivo fat deposition
27. Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice
28. Influence of diet and genetics on metabolic abnormalities in mice treated with HIV protease inhibitors
29. Pharmacokinetic (PK) drug-interaction between amprenavir (APV) and ritonavir (RTV) in HIV-seronegative subjects after multiple, oral dosing
30. Cross-resistance analysis of human immunodeficiency virus type I variants individually selected for resistance to five different protease inhibitors
31. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
32. In vitro selection and characterization of VX-478 resistant HIV-1 variants
33. Resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies: A review
34. HIV drug resistance analysis during clinical studies with the protease inhibitor amprenavir
35. HIV-1 baseline genotype/phenotype and virological response following salvage therapy with Ziagen (abacavir, ABC), amprenavir (APV), and efavirenz (EFV)
36. Agenerase in dual PI combination therapy with saquinavir, indinavir, or nelfinavir: Emergence of resistance
37. Genotypic and phenotypic analysis of HIV-1 isolates from paediatric subjects receiving amprenavir/NRTI combination therapy
38. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
39. Crossresistance to amprenavir in PI treated patients
40. Durability of abacavir/amprenavir/efavirenz combination salvage therapy - Preliminary 48-week response (CNA2007)
41. Pharmacokinetics of 141W94 after single dose administration in HIV-infected children
42. Phase I clinical trial with a novel protease inhibitor for HIV, KVX-478, in healthy male volunteers
43. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
44. Antiviral activity of amprenavir in combination with zidovudine/3TC in plasma and CSF in patients with HIV infection
45. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
46. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor
47. Analysis of amprenavir (APV)/3TC/ZDV in blood and seminal plasma: Penetration of APV into the male genital tract
48. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions
49. Cytochrome P-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94
50. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function
51. Pharmacokinetic drug interactions with amprenavir
52. Pharmacodynamic effects of amprenavir (APV) + ritonavir (RTV) on different vital populations
53. Concomitant ritonavir decreases the clearance of amprenavir - A pharmacokinetic model and simulation of protease inhibitor interaction
54. Pharmacokinetics of 141W94 and indinavir (IDV) after single-dose coadministration in HIV-positive volunteers
55. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficciencyvirus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity
56. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers
57. Pharmacokinetic inter-action between ketoconazole and amprenavir after single doses in healthy men
58. Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children
59. Steady-state plasma pharmacokinetics of amprenavir (APV) 450 mg bid and ritonavir (RTV) 200 mg bid with or without efavirenz (EFV) in HIV-1 infected individuals
60. Efavirenz-induced decrease in plasma amprenavir levels in human immuno-deficiency virus-infected patients and correction by ritonavir
61. Analysis of HIV-1 clinical trials: Statistical magic?
62. Amprenavir (141W94, APV)/3TC/ZDV exerts durable antiviral activity in HIV-1 infected antiretroviral therapy-naïve subjects through 48 weeks of therapy
63. Amprenavir (141W94, APV)/3TC/ZDV exerts potent and durable antiviral activity over 48 weeks of therapy in HIV-1 infected antiretroviral therapy-naive subjects
64. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection
65. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience
66. Amprenavir (141W94, APV USAN approved)/ 3TC/ZDV is superior to 3TC/ZDV in HIV-1 infected antiretroviral naive subjects
67. Increased seminal shedding of HIV during primary infection augments the need for earlier diagnosis and intervention
68. NZT4002: 64 Week analysis of Combivir (COM)-based triple and quadruple therapy in antiretroviral-naive, HIV-1 infected subjects
69. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS Clinical Trials Group Protocol 850)
70. Safety and efficacy of amprenavir in combination with other protease inhibitors
71. A phase III study of amprenavir (APV, Agenerase™) in protease-inhibitor naïve and experienced HIV-infected children and adolescents
72. A phase II study of amprenavir (APV, IWIW94, Agenerase™) in antiretroviral-experienced children with HIV-infection
73. Tolerability profile of amprenavir (APV, 141W94) in combination with various NRTIs
74. Amprenavir (141W94, APV): Review of overall safety profile
75. 'Buffalo hump' in men with HIV-1 infection
76. Lipodystrophy in patients naive to HIV protease inhibitors
77. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
78. Changes in visceral adipose tissue and blood lipids in persons with lipodystrophy switched from protease inhibitor (PI) therapy to efavirenz (EFV)
79. Circulating interferonalpha levels and hypertriglyceridemia in the acquired immuno-deficiency syndrome
80. Amprenavir: A new protease inhibitor with a favorable metabolic profile
81. Fat distribution and retinoid-like symptoms are infrequent in NRTI-experienced subjects treated with amprenavir
82. Amprenavir: A protease inhibitor for the treatment of patients with HIV-1 infection
83. The US FDA has approved twice daily dosing of nelfinavir ['Viracept'; Agouron]